The Future of Vaccines: Beyond Prevention, Towards Treatment and a ‘One Health’ Approach
Table of Contents
Vaccines are rapidly evolving beyond their traditional role in preventing infectious diseases, now poised to treat chronic illnesses, harness personalized medicine, and even safeguard entire ecosystems.
For decades, vaccines have been a cornerstone of global public health, saving an estimated 154 million lives over the past 50 years and contributing to a nearly 40% decrease in infant mortality, according to the World Health Organization. While long considered a mature technology, vaccination is experiencing a resurgence driven by innovative approaches and accelerated by the COVID-19 pandemic. The pandemic’s large-scale validation of mRNA vaccines has fundamentally altered vaccine design, paving the way for a new era of possibilities.
mRNA: A Paradigm Shift in Vaccine Progress
Traditional vaccine development involved lengthy and complex processes of producing and purifying proteins or utilizing attenuated viruses. These methods were often rigid and challenging to personalize. mRNA technology reverses this principle. By simply delivering temporary genetic instructions to cells, they can produce the desired protein themselves. This approach offers unprecedented speed and flexibility. “The same RNA base can be used for very different vaccines, making it possible to develop vaccines in less than two months and opening the door to personalized vaccines,” one expert noted.
Personalized Cancer Vaccines: A Targeted Approach
Cancer vaccines represent a particularly promising application of this new technology. A fragment of a patient’s tumor is removed, its DNA sequenced, and then the specific mutations most likely to trigger an immune response are selected to create a customized RNA vaccine. These vaccines “teach” the immune system to identify and eliminate cancer cells that previously went unrecognized.
“Each cancer vaccine is truly personal
Treating Autoimmune Diseases with Tolerance-Inducing Vaccines
Beyond cancer, vaccines are being explored as a treatment for autoimmune diseases.Professor Jean-jacques Bellier, a pioneer in this field, particularly in the context of Alzheimer’s disease.The goal is to induce specific tolerance without widespread immunosuppression. “Unlike current treatments, we don’t block the entire immune system. We act very specifically on only the cells that recognize the antigen involved in the disease,” he clarifies. With allergies affecting around 30% of the European population-a figure projected to reach 50% by 2050-the development of these tolerant strategies is particularly urgent.
Novel Delivery Methods: Patches, Sprays, and Mucous Membranes
Researchers are also innovating in vaccine governance. Transcutaneous patches and nasal sprays offer simpler, injection-free alternatives, particularly for children. Patches allow for prolonged antigen delivery, perhaps enhancing the immune response. “It has been shown that delivering a vaccine protein gradually is more effective than injecting it all at once,” notes Professor Jean-Daniel Lelièvre, immunologist and director of research at the Vaccine Research Institute.
Spray-based administration, targeting the mucous membranes of the ear, nose, and throat, holds promise for respiratory infections like influenza, RSV, and SARS-CoV-2. “Vaccines that are effective directly on the mucous membranes will allow for better blocking of infection and transmission, and thus improve herd immunity,” Professor Lelièvre explains.
‘One Health’: Vaccinating Across species to Prevent Pandemics
The future of vaccination extends beyond human health.The One Health approach recognizes the interconnectedness of human, animal, and environmental health. many emerging health crises originate in animals,and vaccinating wildlife can protect humans. France’s prosperous elimination of rabies through fox vaccination serves as a prime example.
With climate change increasing the risk of zoonoses-diseases transmissible between animals and humans-animal vaccination is becoming increasingly critical. Vaccine candidates, such as one against Rift Valley fever, are being developed for use in both livestock and humans. However, a researcher observes that “Today, the limits to better vaccination are not only scientific, they are also organizational and political,” emphasizing the need for better coordination between human, veterinary, and environmental health agencies.
